ALNFL Stock Overview
A biotechnology company, engages in the development of natural addiction withdrawal solutions for smokers. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
NFL Biosciences SA Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €2.02 |
| 52 Week High | €3.28 |
| 52 Week Low | €1.33 |
| Beta | 0 |
| 11 Month Change | -2.18% |
| 3 Month Change | 0% |
| 1 Year Change | 27.04% |
| 33 Year Change | -47.53% |
| 5 Year Change | n/a |
| Change since IPO | -45.70% |
Recent News & Updates
Recent updates
Shareholder Returns
| ALNFL | FR Biotechs | FR Market | |
|---|---|---|---|
| 7D | 3.5% | -7.7% | -0.3% |
| 1Y | 27.0% | -26.4% | -3.5% |
Return vs Industry: ALNFL exceeded the French Biotechs industry which returned -26.5% over the past year.
Return vs Market: ALNFL exceeded the French Market which returned -2.5% over the past year.
Price Volatility
| ALNFL volatility | |
|---|---|
| ALNFL Average Weekly Movement | 7.9% |
| Biotechs Industry Average Movement | 6.6% |
| Market Average Movement | 4.5% |
| 10% most volatile stocks in FR Market | 9.2% |
| 10% least volatile stocks in FR Market | 2.2% |
Stable Share Price: ALNFL's share price has been volatile over the past 3 months compared to the French market.
Volatility Over Time: ALNFL's weekly volatility (8%) has been stable over the past year, but is still higher than 75% of French stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2006 | n/a | Ignacio Faus | www.nflbiosciences.com |
NFL Biosciences SA, a biotechnology company, engages in the development of natural addiction withdrawal solutions for smokers. Its pipeline includes NFL-101, a drug candidate for smoking cessation, currently under Phase 2b clinical trials; NFL-201, a drug candidate for cannabis addiction currently in preclinical stage; and NFL-301, a drug candidate for reducing alcohol consumption, currently under in preclinical stage. The company was incorporated in 2006 and is based in Castelnau-le-Lez, France.
NFL Biosciences SA Fundamentals Summary
| ALNFL fundamental statistics | |
|---|---|
| Market cap | €19.85m |
| Earnings (TTM) | €0 |
| Revenue (TTM) | n/a |
n/a
P/E Ration/a
P/S RatioIs ALNFL overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ALNFL income statement (TTM) | |
|---|---|
| Revenue | €0 |
| Cost of Revenue | €0 |
| Gross Profit | €0 |
| Other Expenses | €0 |
| Earnings | €0 |
Last Reported Earnings
n/a
Next Earnings Date
n/a
| Earnings per share (EPS) | 0 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0.0% |
How did ALNFL perform over the long term?
See historical performance and comparison